Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to the Associated Press for an article about NurOwn, a stem cell-based therapy for patients with ALS, or amyotrophic lateral sclerosis. At the time, the treatment was awaiting approval by the U.S. Food and Drug Administration (FDA). The FDA eventually voted against the therapy.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH